CHU de Nantes;INSERM;Immunomedics, Inc.;University of Nantes
发明人:
Patrice Chevallier,Francoise Kraeber-Bodere,David M. Goldenberg
申请号：
US15088491
公开号：
US20160296648A1
申请日:
2016.04.01
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention relates to use of 90Y-conjugated anti-CD22 antibody for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Preferably the anti-CD22 antibody is epratuzumab tetraxetan. More preferably, the radiolabeled antibody is administered at a dosage of between 2.5 and 10.0 mCi/m2, most preferably on days 1 and 8 of the cycle. In specific embodiments, the dosage may be 2.5, 5.0, 7.5 or 10.0 mCi/m2. The radiolabeled antibody is capable of inducing a complete response in individuals with relapsed/refractory ALL.
